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Factors related to the incidence of CTCAE 3.0 Grade 2 or worse 
pulmonary fibrosis induced by neoadjuvant platinum-based 
chemotherapy and thoracic radiotherapy: A prospective study
Xie, Liyi; Fan, Ming; Cai, Xuwei; Jiang, Guoliang 
Department of Radiation Oncology,Cancer Hospital,Fudan University, 
Shanghai, China
Purpose: To investigate,prospectively,clinical,physical parameters 
and changes in serum interleukin-1α(IL-1α), IL-1β, IL-6,IL-7, tumor 
necrosis factor-α (TNF-α), transforming growth factor-β1(TGF-β1) 
and manganese superoxide dismutase (MnSOD) as indicators for CT-
CAE3.0 ≥Grade2 pulmonary ﬁbrosis induced by neoadjuvant platinum-
based chemotherapy and thoracic radiotherapy(TRT).
Methods: Between January and December 2004, 86 patients (66 with 
lung cancer,10 esophageal cancer, 5 malignant thymoma, 5 mediasti-
num tumor) who received incidental thoracic irradiation and neoadju-
vant platinum-based chemotherapy were enrolled in this prospective 
study. There were 9 females and 77 males(median age, 57 years; range, 
19-74). The median follow-up was 96 days (range, 30-557). All patients 
received neoadjuvant platinum-based chemotherapy. Chemo-regimen 
included NP, NIP, EP, IEP and CAP. The medium pre-RT cycle was 
one (range, 1-6). Radiation dose ranged 30-66Gy.Cad-plan™v6.08 and 
Pinnacle3™v7.0 treatment planning system were applied to generate 





10Gy increments. Serial serum concentration of IL-1α, IL-1β, IL-6, 
IL-7, TNF-α, TGF-β1 and MnSOD were determined by enzyme-
linked immunosorbent assay (ELISA) prior to and weekly during RT. 
Since great inter-patient divergence was revealed for baseline serum 
cytokines and MnSOD levels,we calculated week1/pre-RT ratios (w1/0 
ratio, deﬁned as serum concentration in the 1st week of RT/Pre-RT 
level) as surrogates.On univariate analysis,various dosimetric,serum 
cytokines,serum MnSOD,smoking history(<20 pack-year vs.≥20 
pack-year) and clinical parameters (conventional RT vs.non-conven-
tional RT, age) were studied. Hazard ratios(HRs) were estimated by 
Cox proportional hazard models for indicators to CTCAE3.0 Grade≥2 
pulmonary ﬁbrosis.
Results: Six of 86(7%) patients developed CTCAE3.0 Grade≥2 pulmo-
nary ﬁbrosis. Two developed Grade2 ﬁbrosis (proportion of total lung 
volume that is ﬁbrotic is 25-<50%), 2 Grade3 (50-<75%), 2 Grade4 
(≥75% or honeycombing) and 0 Grade5 (death). On univariate analysis, 
no single parameter signiﬁcantly correlated with severe pulmonary 
ﬁbrosis.IL-7 w1/0 ratio approached marginal statistical signiﬁcance 
(p=0.06). On multivariate analysis,baseline FEV1(p=0.0352, HR 
0.062) was signiﬁcantly associated with ≥Grade2 pulmonary ﬁbrosis.
A trend towards signiﬁcant correlation with ﬁbrosis was observed for 
IL-1β w1/0 ratio and TGF-β1 w1/0 ratio,p=0.0716(HR 7.929) and 
p=0.0925(HR 2.561),respectively. 
Conclusions: Baseline FEV1 seemed to signiﬁcantly associate with 
CTCAE3.0 Grade≥2 pulmonary ﬁbrosis in this group of patients.IL-1β 
w1/0 ratio and TGF-β1 w1/0 ratio were meanwhile marginally signiﬁ-
cant indicators. However,since only a few events were observed,care 
should be taken in interpreting the present ﬁndings.
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Results of hypofractionated radiotherapy (2 x 8 Gy) for patients 
with brain metastases from lung cancer
Bolukbasi, Yasemin; Yalman, Deniz; Akcay, Cimen; Ozkok, Serdar 
Ege University, Izmir, Turkey
Purpose: Brain metastases will develop in 25% of patients with lung 
cancer at some point in the course of their disease and radiotherapy is 
the mainstay of treatment for the palliation of brain metastases. The 
aim of this study is to evaluate the clinical and radiologic response 
rates, toxicity and tolerability of 2 x 8 Gy whole brain radiotherapy 
(WBRT) in lung cancer patients with brain metastases and to identify 
the prognostic factors for survival.
Materials and Methods: 2 x 8 Gy WBRT was performed in 126 lung 
cancer patients with brain metastases during 2002 and 2006 at the 
Radiation Oncology Department of Ege University Hospital.
Results: Twenty-three patients had small cell and 103 had nonsmall 
cell lung cancer. Pretreatment median Karnofsky performance score 
was 70 (range 20-90). In 62 patients (49.2%) the brain metastases were 
synchronous with the primary tumor. In metachronous metastases 
median time to metastases was 6 months (range 1-25 months). Median 
number of metastatic foci was 3 (range 1-8). Treatment was tolerated 
well. Clinical response rates were as follows: complete response 31%; 
good partial response 30.2%; partial response 21.4%; stable disease 
7.9% and progressive disease 5.6%. Radiological response was evalu-
ated in 54 patients and the response rates were as follows: complete 
response 7.4%; good partial response 5.6%; partial response 35.2%, 
stable disease 44.4% and progressive disease 7.4%. Median palliation 
and survival duration was 57 and 80 days respectively. Two and 6-
month survival rates were 59.5% and 25.4% respectively. Performance 
status, age, hemoglobin level, metachronous metastases, localization, 
status of the primary tumor, response to steroid treatment, response 
rate, presence of other metastases, chemotherapy, serum lactate de-
hydrogenase level were identiﬁed as prognostic factors for survival. 
According to “Recursive Partioning Analysis” 6 month-survival rates 
for Groups 1, 2 and 3 were 61.5%, 41.6% and 33.9% respectively 
(p=0.002). Reirradiation was performed in 11 patients within a median 
of 5 months (range 4-12 months). 
Conclusion: Hypofractionated radiotherapy of 2 x 8 Gy provides simi-
lar palliation and survival rates when compared with other fractionation 
schedules and it is tolerable. The prognostic factors such as perfor-
mance status, age, status of the primary tumor, response to steroid treat-
ment, presence of other metastases, and serum lactate dehydrogenase 
level are also consistent with the literature. However the late morbidity 
of this schedule is unknown at the moment so its use could be restricted 
to patients with poor performance status with a short life expectancy.
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Long-term results of adjuvant radiotherapy in patients with 
resected non small cell lung cancer
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Purpose: To report the long term results of adjuvant radiotherapy in 
resected non small cell lung cancer patients.
Methods And Materials: We retrospectively reviewed the medical 
records of 100 non small cell lung carcinoma patients ( 93 men and 7 
women; median age 58, range 35-75) who received adjuvant radio-
therapy between January 1994 and December 2004 at Ege University 
Department of Radiotherapy. The most frequently performed surgical 
procedure was lobectomy (62), followed by pneumonectomy (25), 
wedge resection (7) and bilobectomy (6). The patients were pathologi-
cally staged. Radiotherapy was delivered to patients with positive 
margins or following a wedge resection in stage I disease. Nine patients 
received platinum-based neoadjuvant chemotherapy prior to surgery. 
Nineteen patients received adjuvant chemotherapy prior to radiotherapy 
and 22 patients received adjuvant chemotherapy after radiotherapy. 
Radiotherapy was administered to the tumor bed and/or mediastinum 
using Co 60 or 6 MV photons. The median postoperative radiotherapy 
dose was 50 Gy using conventional fractionation. 
A Kaplan-Meier estimate of local control (LC), distant metastasis free 
survival (DFS), and overall survival (OS) was calculated. 
Results: Pathologic stages included I (n =18), II (n = 45), IIIA (n = 
31), and IIIB (n = 6). After a median follow-up of 52 months (6-169) 
median survival was 61 months. The 5 and 10 years OS, LC and DFS 
rates for all patients were 50%, 77%, 36% and 34%, 65%, 9% respec-
tively. The over all survival for stages I, II and III were 58%, 55% and 
38% respectively at 5 years. Only pneumonectomy and low KPS scores 
were found to have a negative impact on survival(P= 0.01 and 0.03). 
For local contol, the total number of involved lymph nodes and KPS 
were found as signiﬁcant prognostic factors(P=0.03 for both two). For 
DFS, the only correlation was found for nodal stage(p=0.03). 
Conclusion: Surgery and postoperative radiotherapy can provide a 
high locoregional control rate (over 70%) however, the efﬁcacy of 
postoperative radiotherapy decreases with pneumonectomy, low KPS 
and greater number of involved lymph nodes. 
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Concomitant treatment of brain metastasis from non-small cell 
lung cancer with whole brain radiotherapy and Gefitinib
Xu, Yaping1 Ma, Shenglin2 Zhenfu, Fu2 Qinghua, Deng2 Xinmin, Yu2 
1 Department of Radiation Oncology, Hangzhou, Zhejiang, China 2 De-
partment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, 
Zhejiang, China 
Background: Brain metastases (BM) represent one of the most fre-
quent complications related to non-small lung cancer (NSCLC), and 
their treatment continues to evolve. We have evaluated the activity, 
toxicity and the impact on Quality of Life (QoL) of a concomitant treat-
ment with whole brain radiotherapy (WBRT) and Geﬁtinib in patients 
with brain metastases from NSCLC in a prospective study. 
Methods: 21 patients were enrolled and received 40 Gy/20f/4w WBRT 
with concomitant Geﬁtinib (250 mg /day). The primary end points were 
clinical symptoms and objective response. 
Results: 4 patients had a complete response, 13 patients had a partial 
response, 3 patients had stable disease, while 1 patient had progression 
disease. The overall response rate was 81.0%. The most frequent toxici-
ties included rash (85.7%) and diarrhea (42.9%), and only 3 patients 
developed a grade 3 diarrhea. Gender and the recursive partitioning 
analysis (RPA) were found to be predictive factors for response in 
patients. There were statistically signiﬁcant changes between pretreat-
ment and post-treatment in all domains of QOL but additional concerns 
with the FACT-L. 
Conclusion: We concluded that this treatment was well tolerated, with 
an encouraging objective response rate and a signiﬁcant improvement 
in quality of life. Our study found a high level of satisfaction for QoL, 
this provides useful information to share with patients in discussions 
regarding molecular targeting treatment of these lesions.
NSCLC: Surgery
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Prognostic impact of platelet counts on survival after surgery in 
stage I non small cell lung cancer
Aerts, Joachim G. 
Sint Franciscus Gasthuis/Erasmus MC, Rotterdam, The Netherlands
Background: From recent studies on adjuvant chemotherapy in oper-
ated patients with non-small cell lung cancer it was established that the 
beneﬁcial effect of adjuvant therapy in stage I disease is questionable. 
But in stage I disease recurrences do appear. Identifying patients prone 
for recurrent disease would be highly desirable. A number of studies 
reported an association between thrombocytosis and survival in patients 
with lung cancer. The prognostic impact of platelet counts was tested 
in a series of patients who underwent surgery for stage I non-small cell 
lung cancer (NSCLC).
Methods: Electronic records from the Rotterdam Cancer Registry 
were used to select patients who underwent surgery for stage I NSCLC 
in two hospitals during the period 1989-2002. Information on platelet 
count and vital status was gathered retrospectively. The study group 
(n=354) was stratiﬁed by platelet count (<150, 150-225, 226-400, ≥ 
400) and variation in actuarial survival was assessed with the log-rank 
test and with proportional hazard analysis.
Results: Univariate survival analysis suggested age (p=0.12), extent 
of surgery (p=0.13) and platelet count (p=0.0003) as prognostic factors 
(table). Absolute ﬁve-year survival by platelet count subgroup was 
36%, 68%, 68% and 35%, respectively. In multivariate analysis, the 
hazard ratios for platelet count <150 and >=400 were 3.2 and 3.1, as 
compared with normal platelet counts. 
Conclusions: Low platelet counts and thrombocytosis were associated 
with poorer survival in patients with stage I NSCLC. A novel ﬁnding 
is that also low platelet counts seem to inﬂuence survival. Given the 
similarity in survival in the groups with high and low platelet counts, 
a measurement error should not be ruled out. Platelet production may 
actually have been stimulated in these patients but pseudothrombo-
cytopenia may have occurred due to platelet agglutination. Research 
regarding the biological mechanism behind this association may reveal 
new treatment options. Adjuvant therapy should be considered also in 
patients with stage I disease with abnormal platelet counts. 
